| Autor: |
Davis, S. Lindsey, Hartman, Sarah J., Bagby, Stacey M., Schlaepfer, Marina, Yacob, Betelehem W., Tse, Tonia, Simmons, Dennis M., Diamond, Jennifer R., Lieu, Christopher H., Leal, Alexis D., Cadogan, Elaine B., Hughes, Gareth D., Durant, Stephen T., Messersmith, Wells A., Pitts, Todd M. |
| Rok vydání: |
2022 |
| DOI: |
10.6084/m9.figshare.21435510 |
| Popis: |
Additional file 1: Supplemental Table 1. Prototypical DNA Damage Repair Mutations in CRC Models Utilized in this Study. Supplemental Figure 1. Effect of AZD0156 and SN38 on proliferation in CRC cell lines. AZD0156 dose 50nM, SN38 dose 10nM. Percent confluence relative to vehicle at 120 hours as assessed by Incucyte ZOOM. Supplemental Figure 2. Effect of AZD0156 and SN38 on proliferation in additional CRC cell lines. Percent confluence relative to vehicle as measured by IncuCyte ZOOM™ over 120 hours in an additional 8 CRC cell lines treated with AZD0156 50 nM and 100 nM and SN38 10 nM, alone and in combination. Supplemental Figure 3. Statistical evaluation of synergy based on Bliss independence. Comparison of single agent and combination effect as assessed by Incucyte ZOOM™ to Bliss independence, derived from individual groups by computing survival fraction under the assumption that treatments act independently, as per Demidenko E, et al. [12]. Supplemental Figure 4. In vivo effects of AZD0156 and chemotherapy in CRC PDX models. (A) Effect of AZD0156, irinotecan, and 5FU, alone and in combination in the CRC026 and CRC102 PDX models. Additional treatment groups added to data provided in Figure 5 of the main text. Doses of irinotecan and 5FU were reduced in single-agent and combination arms at day 11 in the CRC026 model due to its sensitivity to these single agents. (B) Specific Growth Rates of CRC026 and CRC102. Supplemental Figure 5. (A) Effect of AZD0156, irinotecan, and 5FU, alone and in combination in additional CRC001 and CRC042 PDX models. (B) Specific growth rates of CRC001 and CRC042. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
